Phaseline

Companies › Helixon Biotechnology (Suzhou)

Helixon Biotechnology (Suzhou): clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Other; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
HXN6005–Phase 1Healthy Volunteers (HV)Mar 2027
HX15001–Phase 1Healthy Volunteers–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06999720HX15001Phase 1Healthy VolunteersOtherSep 2026
NCT07449741HXN6005Phase 1Healthy Volunteers (HV)OtherMar 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.